Os Therapies Inc. (OSTX) intrinsic value & 10-year financials
Os Therapies Inc. (OSTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.32
- Market cap
- $38.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 201.9%
- Free cash flow (FY2025)
- -$14.7M
OSTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$28.8M | -$0.98 | -$14.7M | — | 507.4% |
| FY2024 | — | -$8.9M | -$0.88 | — | — | 60.7% |
| FY2023 | — | -$7.8M | -$1.46 | — | — | 37.5% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
OS Therapies Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
OS Therapies Inc has earned high returns on invested capital, averaging 34.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
OS Therapies Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
OS Therapies Inc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.